TFA Therapeutics (RAJAF) Total Liabilities (2020 - 2025)

TFA Therapeutics has reported Total Liabilities for 6 years, with the latest figure at $5.2 million in Q4 2025.

• On a quarterly basis, Total Liabilities rose 3.86% year-over-year to $5.2 million in Q4 2025; TTM through Dec 2025 was $5.2 million, a 3.86% increase from a year earlier, with the FY2025 full-year figure at $5.2 million, up 3.86% from the prior year.
• Total Liabilities was $5.2 million for Q4 2025 at TFA Therapeutics, up from $5.0 million in the prior quarter.
• The five-year high for Total Liabilities was $5.2 million in Q4 2025, with the low at $2.0 million in Q3 2023.
• Average Total Liabilities over 5 years is $3.7 million, with a median of $3.5 million recorded in 2021.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities dropped 13.64% in 2022, then jumped 42.69% in 2024.
• Over 5 years, Total Liabilities stood at $3.5 million in 2021, then decreased by 13.64% to $3.1 million in 2022, then increased by 14.64% to $3.5 million in 2023, then surged by 42.69% to $5.0 million in 2024, then increased by 3.86% to $5.2 million in 2025.
• The last three Total Liabilities figures came in at $5.2 million (Q4 2025), $5.0 million (Q4 2024), and $3.5 million (Q4 2023), per Business Quant data.